Supriya Lifescience collaborates with Plasma Nutrition for protein technology
Supriya Lifescience jumps on bargain hunting
Supriya Lifescience Announces Rajeev Kumar Jain as CEO & Key Managerial Personnel
Supriya Life gains on securing CEP for anti-histamine therapy
Supriya Lifescience falls 6% on CEO`s resignation
Supriya Lifescience Financial Year 2021-2022 Q3
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,n2015, we are enclosing the investor presentation.
Supriya Lifescience gets reality check; Hikal back in demand after 11 sessions
Un-Audited Financial Results For The Quarter Ended December 31, 2021
EDINA, Minn.--(BUSINESS WIRE)--TTC Oncology (“TTC” or the “Company”), an early-stage biotech company, preparing to enter phase 2 clinical trials, is innovating safer solutions for the treatment of metastatic breast cancer, whose mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients, today announced the launch of its equity crowdfunding campaign on WeFunder with an initial investment of $100,000.